ONCOVALUE at ISPOREurope 2026 | Poster EE243

From 9-12 November, the ONCOVALUE project participated in ISPOR Europe 2026 in Vienna, presenting two posters showcasing different approaches to generating reliable evidence and assessing the value of cancer treatments.

Building Trust in Real-World Evidence: Validation of Data, Methods and AI Solutions in European Cancer Centres

This poster highlighted ONCOVALUE’s multi-level validation framework for assessing the quality, usability and reliability of real-world data, Health Technology Assessment (HTA) methodologies and AI-based solutions in oncology.

The approach aims to strengthen confidence in RWE and support its integration into HTA processes and healthcare decision-making.

Poster EE243 | Optimising Pembrolizumab Dosing in Advanced NSCLC

Pembrolizumab has changed outcomes for patients with advanced NSCLC, but its high cost puts pressure on health system sustainability. One way to ease that pressure is dosing: the Dutch Society of Medical Oncology (NVMO) recommends weight-based bands (100/150/200 mg Q3W). Many patients, however, still get the fixed 200 mg dose.

Key findings:

  • 61% received above-guideline doses (>2.3 mg/kg), mostly because of the fixed 200 mg dose
  • Within-guideline dosing showed numerically longer survival (median OS 28.4 vs 18.2 months). The difference was not statistically significant.

Lower, weight-based doses don’t appear to compromise effectiveness and could cut costs substantially. A discrete event simulation will be built next to estimate the cost-effectiveness of the two dosing approaches.

Congratulations to Zainab Al-Khayat, who presented this poster at ISPOR Europe 2026 on behalf of co-authors Nora Franzen, Mariska Rijnen, Sushil Badrising, Anne Bressers, Madelon Voets, Sabine Siesling, Wim van Harten and Valesca Retèl.

Access the poster here!